CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of breast cancer.
  
  LEARNING OBJECTIVES

  • Develop an optimal approach to adjuvant therapy for patients with ER-positive breast cancer (BC), considering the implications of patient age, tumor size/grade and other clinicopathologic factors.
  • Consider published data to guide the use of biomarkers and genomic classifiers in assessing risk and customizing therapy for patients with hormone receptor-positive BC in the adjuvant setting.
  • Understand the biologic rationale for and available data with CDK4/6 inhibitors in localized ER-positive, HER2-negative BC, and assess the potential role of these agents in this setting.
  • Develop an evidence-based algorithm for the treatment of advanced hormone receptor-positive pre- and postmenopausal BC, including endocrine, biologic and chemotherapeutic agents.
  • Recall the FDA indications for the commercially available CDK4/6 inhibitors, and discern how these agents can be optimally employed in the nonresearch care of patients with ER-positive metastatic BC.
  • Appraise available research data and clinical investigators’ perspectives to formulate appropriate clinical recommendations for patients who experience disease progression on CDK4/6 inhibitors in combination with hormonal therapy.
  • Recognize the approval of and published efficacy and safety data with the PI3 kinase inhibitor alpelisib in combination with fulvestrant for patients with metastatic HER2-negative BC harboring a PIK3CA mutation, and consider the diagnostic and therapeutic implications of these findings on nonresearch care.
  • Develop an understanding of available data with and potential clinical roles of other investigational agents and strategies to facilitate referral for clinical trial opportunities or prepare for the future availability of these approaches.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Virginia Kaklamani, MD, DSc
  Professor of Medicine
  Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
  AB Alexander Distinguished Chair in Oncology
  Associate Director for Clinical Research
  Leader of the Breast Cancer Program
  UT Health San Antonio
  The University of Texas MD Anderson Cancer Center
  San Antonio, Texas
  
  Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Athenex, Celldex Therapeutics, Eisai Inc, Immunomedics Inc, Puma Biotechnology Inc; Contracted Research: Eisai Inc; Data and Safety Monitoring Board/Committee: Bristol-Myers Squibb Company; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Genomic Health Inc, Novartis, Pfizer Inc, Puma Biotechnology Inc.
  
  Sara M Tolaney, MD, MPH
  Associate Director, Susan F Smith Center for Women’s Cancers
  Director of Clinical Trials, Breast Oncology
  Director of Breast Immunotherapy Clinical Research
  Senior Physician
  Breast Oncology Program
  Dana-Farber Cancer Institute
  Assistant Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Athenex, Bristol-Myers Squibb Company, Celldex Therapeutics, Eisai Inc, G1 Therapeutics, Genentech, a member of the Roche Group, Immunomedics Inc, Lilly, Merck, NanoString Technologies, Nektar, Novartis, Odonate Therapeutics, OncoPep, Paxman, Pfizer Inc, Puma Biotechnology Inc, Sanofi Genzyme, Seagen Inc, Silverback Therapeutics; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Cyclacel Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Immunomedics Inc, Lilly, Merck, NanoString Technologies, Nektar, Novartis, Odonate Therapeutics, Pfizer Inc, Sanofi Genzyme, Seagen Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Merck, Puma Biotechnology Inc and Seagen Inc.
  
  Release date: November 2020
  Expiration date: November 2021